Mir-221 promotes trastuzumab-resistance and metastasis in her2-positive breast cancers by targeting PTEN

BMB Reports

Volumn 47, Issue 5, 2014, Pages 268-273

  Ye, Xingming ^a,b   Bai, Wendong ^a   Zhu, Huayu ^a,c   Zhang, Xiao ^a   Chen, Ying ^b   Wang, Lei ^a   Yang, Angang ^a   Zhao, Jing ^a   Jia, Lintao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Erbp2 HER2; Metastasis; Mir 221; PTEN; Trastuzumab resistance

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; MICRORNA; MIRN221 MICRORNA, HUMAN; MONOCLONAL ANTIBODY; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; RNA; TRASTUZUMAB; TUMOR MARKER;

APOPTOSIS; ARTICLE; BREAST TUMOR; DRUG ANTAGONISM; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; METASTASIS; TUMOR CELL LINE; TUMOR INVASION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 84902009145     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.5.165     Document Type: Article

References (28)

1. Andersson, J., Linderholm, B., Greim, G., Lind, B., Lindman, H., Tennvall, J., Tennvall-Nittby, L., Pettersson-Skold, D., Sverrisdottir, A., Soderberg, M., Klaar, S. and Bergh, J. (2002) A population-based study on the first forty-eight breast cancerpatients receiving trastuzumab (Herceptin) on a named patientbasis in Sweden. Acta. Oncol., 41: 276-281.
2. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G. and Slamon D. J. (1999) Multinational studyof the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressingmetastatic breast cancer that has progressed after chemotherapyfor metastatic disease. J. Clin. Oncol., 17: 2639-2648.
3. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A. and McGuire,W. L. (1987) Human breast cancer: correlationof relapse and survival with amplification of theHER-2/neu oncogene. Science, 235: 177-182.
4. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. andUllrich, A. (1989) Studies of the HER-2/neu proto-oncogenein human breast and ovarian cancer. Science, 244: 707-712.
5. Owens, M. A., Horten, B. C. and Da Silva, M. M. (2004) HER2 amplification ratios by fluorescence in situ hybridization andcorrelation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer, 5: 63-69.
6. Ross, J. S, Fletcher, J. A, Bloom, K. J., Linette, G. P., Stec, J., Symmans, W. F., Pusztai, L. and Hortobagyi, G. N. (2004) Targeted therapy in breast cancer: The HER-2/neu gene andprotein. Mol. Cell Proteomics, 3: 379-398.
7. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C. andNorton, L. (1996) Phase II study of weekly intravenous recombinanthumanized anti-p185HER2 monoclonal antibodyin patients with HER2/neu-overexpressing metastaticbreast cancer. J. Clin. Oncol., 14: 737-744.
8. Menard, S., Fortis, S., Castiglioni, F., Agresti, R. and Balsari, A. (2001) HER2 as a prognostic factor in breast cancer. Oncology 61(Suppl 2),67-72.
9. Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Philips, R. N., Ross, J. S.,Wolman, S. R. andFlow, K. J. (1997) HER-2/neu gene amplification characterizedby fluorescence in situ hybridization: poor prognosisin node-negative breast carcinomas. J. Clin. Oncol., 15: 2894-2904.
10. Bartel, D. P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116: 281-297.
11. Ahmad, A., Aboukameel, A., Kong, D.,Wang, Z. W., Sethi, S., Chen, W., Sarkar, F. H. and Raz, A. (2011) Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymaltransition regulated by miR-200 in breast cancer cells. Cancer Res., 71: 3400-3409.
12. Adams, B. D., Guttilla, I. K. and White, B. A. (2008) Involvement of microRNAs in breast cancer. Semin. Reprod. Med., 26: 522-536.
13. Zhang, C. Z., Kang, C. S., Pu, P. Y., Wang, G. X., Jia, Z. F., Zhang, A. L., Han, L. and Xu, P. (2009) Inhibitory effect ofknocking down microRNA-221 and microRNA-222 on gliomacell growth in vitro and in vivo. Zhonghua Zhong Liu ZaZhi, 31: 721-726.
14. Galardi, S., Mercatelli, N., Giorda, E., Massalini, S., Frajese, G. V., Ciafre, S. A. and Frarace, M. G. (2007) miR-221 andmiR-222 expression affects the proliferation potential of humanprostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem., 282: 23716-23724.
15. Zhang, C. Z., Han, L., Zhang, A. L., Fu, Y. C., Yue, X., Wang, G. X., Jia, Z. F., Pu, P. Y., Zhang, Q. Y. and Kang, C. S. (2010) MicroRNA-221 and microRNA-222 regulate gastric carcinomacell proliferation and radioresistance by targeting PTEN. BMC Cancer 10, 367.
16. Felicetti, F., Errico, M. C., Bottero, L., Segnalini, P., Stoppacciaro, A., Biffoni, M., Felli,N., Matttia, G., Petrini, M.,Colombo, M. P., Peschle, C. and Care, A. (2008) The promyelocyticleukemia zinc finger microRNA-221/222 pathwaycontrols melanoma progression through multiple oncogenicmechanisms. Cancer Res., 68: 2745-2754.
17. Rao, X., Di, L. G., Li, M., Feng, F., Declin, C., Hartman-Frey, C., Burow, M. E., lvan, M., Croce, C. M. and Nephew, K. P. (2011) MicroRNA-221/222 confers breast cancer fulvestrantresistance by regulating multiple signaling pathways. Oncogene, 30: 1082-1097.
18. Thompson, C., Macdonald, G. and Mueller, C. R. (2011) Decreased expression of BRCA1 in SK-BR-3 cells is the resultof aberrant activation of the GABP Beta promoter by anNRF-1-containing complex. Mol. Cancer, 10: 62-79.
19. Miller, T. W., Rexer, B. N., Garrett, J. T. and Arteaga, C. L. (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implicationsin breast cancer. Breast Cancer Research 13, 224.
20. Hollander, M. C., Blumenthal, G. M. and Dennis, P. M. (2011) PTEN loss in the continuum of common cancers, rare syndromesand mouse models. Nat. Rev. Cancer, 11: 289-301.
21. O'Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M. J., Crown, J., O'Donovan, N. andSlaman, D. J. (2010) Activated phosphoinositide 3-Kinase/AKT signaling confers resistance to trastuzumab but not lapatinibmol. Cancer Ther., 9: 1489-1502.
22. Li, J., Zhang Y., Zhao, J., Kong, F. and Chen, Y. (2011) Overexpression of miR-22 reverses paclitaxel-induced chemoresistancethrough activation of PTEN signaling inp53-mutated colon cancer cells. Mol. Cell Biochem. 357(1-2), 31-38.
23. Liu, Z. L., Wang, H., Liu, J. and Wang, Z. X. (2013) MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo-or radio resistance in non-small cell lungcancer cells by targeting PTEN. Mol. Cell Biochem. 372(1-2), 35-45.
24. Wu, Z., He, B., He, J. and Mao, X. (2013) Upregulation ofmiR-153 promotes cell proliferation via downregulation ofthe PTEN tumor suppressor gene in human prostate cancer. Prostate, 73: 596-604.
25. Eccles, S. A. (2002) The role of c-erbB-2/HER2/neu in breastcancer progression and metastases. J. Mammary Gland Biol. Neoplasia, 6: 393-406.
26. Esteva, F. J., Sahin, A. A., Critofanilli, M., Arun, B. andHortobagyi, G. N. (2002) Molecular prognostic factors forbreast cancer metastases and survival. Sem. Radiat. Oncol., 12: 319-328.
27. Garofalo, M., Di, L. G., Romano, G., Nuovo, G., Suh, S. S., Ngankeu, A., Taccioli, C., Pichiorri,F., Alder, H., Secchiero, P., Gasparini, P., Gonelli, A., Costinean, S., Acunzo, M., Condorelli, G. and Croce, C. M. (2009) miR-221 & 222 regulateTRAIL resistance and enhance tumorigenicity throughPTEN and TIMP3 downregulation. Cancer Cell, 16: 498-509.
28. Johanna, C. B., Susan, M. D., Harold, J. B., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R. and Winer, E. (2003) Central nervous system metastases in women who receivetrastuzumab-based therapy for metastatic breastcarcinoma. Cancer, 97: 2972-2977.